Raloksifeeni

Raloxifene is a selective estrogen receptor modulator (SERM) used primarily for the prevention and treatment of osteoporosis in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer. Raloxifene works by mimicking the effects of estrogen in some tissues, such as bone, while blocking the effects of estrogen in others, such as breast and uterine tissue. This tissue-specific action is a hallmark of SERMs.

In the context of osteoporosis, raloxifene helps to maintain bone density by reducing bone resorption, the process by which bone tissue is broken down. By inhibiting bone resorption, it helps to prevent fractures. For breast cancer risk reduction, its anti-estrogenic effect in breast tissue is thought to be responsible for its protective action.

Raloxifene is administered orally, typically once daily. Common side effects can include hot flashes, leg cramps, and an increased risk of blood clots, such as deep vein thrombosis and pulmonary embolism. Due to the increased risk of thromboembolic events, raloxifene is contraindicated in women with a history of these conditions. It is important for patients to discuss their medical history and potential risks with their healthcare provider before starting raloxifene.